The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 21, 2021

Filed:

Nov. 09, 2017
Applicants:

Industry-academic Cooperation Foundation, Yonsei University, Seoul, KR;

Institute for Basic Science, Daejeon, KR;

Inventors:

Dong Wook Kim, Seoul, KR;

Jin Soo Kim, Seoul, KR;

Chul Yong Park, Seoul, KR;

Duk Hyoung Kim, Gyeonggi-do, KR;

Jung Eun Kim, Seoul, KR;

Jiyeon Kweon, Seoul, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C12N 5/074 (2010.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01); A61K 35/545 (2015.01); C07K 14/755 (2006.01); C12N 15/113 (2010.01); A61K 35/12 (2015.01);
U.S. Cl.
CPC ...
A61K 48/005 (2013.01); A61K 35/12 (2013.01); A61K 35/545 (2013.01); A61K 48/00 (2013.01); C07K 14/755 (2013.01); C12N 5/0696 (2013.01); C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12N 15/113 (2013.01); C12N 2310/20 (2017.05); C12N 2501/73 (2013.01); C12N 2506/09 (2013.01);
Abstract

The present invention provides a method for inducing an inversion of normal blood coagulation factor VIII (F8) gene, a method for correcting an inversion of blood coagulation factor VIII gene in which the inversion has occurred, and a Hemophilia A patient-derived induced pluripotent stem cell in which the inversion is corrected, constructed using the same. The method of the present invention effectively reproduces the inversion of intron 1 and intron 22 of the F8 gene, which is responsible for the majority of severe hemophilia A, and thereby may be effectively used for studying the development mechanism of hemophilia A and as a research tool for screening therapeutic agents. The inversion-corrected induced pluripotent stem cell constructed according the method of the present invention enables an efficient and fundamental treatment for hemophilia A by restoring a genotype in which mutation has occurred to a wild type-like state, without limitation via normal gene or protein delivery.


Find Patent Forward Citations

Loading…